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Background: The management of mitral regurgitation (MR) is challenging — patients may be asymptomatic,
oligosymptomatic, older with comorbidities, or clinically symptomatic and not appropriate for surgery. The cur-
rent review assesses morbidity, mortality, and risk factors associated with functional and organic MR, with a
focus on severe MR.
Methods:A structured literature reviewwas conducted inMEDLINE, Embase, the Cochrane Library, and via hand-
searching of conference proceedings. Prospective randomised controlled trials and observational studies includ-
ing adult patients with MR reporting on treatment response rates, survival, time-to-treatment failure, quality of
life, and adverse events were eligible for inclusion.
Results: In total, 32 publications met the inclusion criteria (9 in functional, 18 in organic, and 5 in functional/
organic). Despite study heterogeneity, an increased risk of mortality and morbidity was observed which in-
creasedwithMR severity. Risk factors associatedwithmortality andmorbidity included advancing age, presence
of atrial ﬁbrillation, increasing effective regurgitant oriﬁce, ejection fraction, left ventricle end systolic diameter,
diabetes, and increasing New York Heart Association class.
Conclusions: The current review represents one of the most comprehensive conducted in the medical/
conservative management of MR. An increased risk of mortality and morbidity, which appeared to rise with
greater severity, was associated with MR (versus no MR). An unmet need exists in the management of patients
with severe symptomatic MR and a high surgical risk as they have a poor prognosis and limited treatment
options. Further research into alternative medical strategies and patient management is needed to improve
prognoses and reduce mortality and morbidity.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Mitral regurgitation (MR) is the second most common valvular dis-
ease necessitating surgery in Europe [1]. It is characterised by the retro-
grade ﬂow of blood from the left ventricle (LV) into the left atrium (LA)
[2,3] and can be classiﬁed as functional or organic depending on the
mechanism. Organic MR (OMR) is the predominant aetiology (speciﬁ-
cally the degenerative form) [2,4] and is due to structural abnormalities
in the leaﬂets or sub-valvular apparatus [2,3]. In contrast, in functional
MR (FMR) the valve and chordae are structurally normal and regurgita-
tion is caused by dilated cardiomyopathy or LV ischaemia [2,3].man Business Centre, Talisman
9 241281.
ell).
ability and freedom frombias of
land Ltd. This is an open access articlThe management of MR is challenging as patients with MR may be
asymptomatic, minimally symptomatic (oligosymptomatic), symptom-
atic but unsuitable for surgery (such as older patients with severe co-
morbidities), have unresolved MR after surgery, and preoperative risk
evaluations remain difﬁcult. Although in symptomatic MR surgery is
considered, the management of asymptomatic MR is a contentious
issue [5,6] and no randomised controlled trials (RCTs) exist to support
a particular strategy [5]. Furthermore, medical management gives limit-
ed symptomatic beneﬁt in patients with MR [3].
Typically, in symptomatic patients with OMR and a LV ejection frac-
tion (LVEF) N30%who are not contraindicated to surgical treatment, the
main approach is surgery whereasmedical therapywill be considered if
LVEF b30% and the patient is not refractory to treatment [5]. Surgery
may also be considered in patients with LVEF b30% who are refractory
to treatment [5]. Valve repair is generally considered the optimal surgi-
cal treatment strategy in patients with severe OMR, although mitral
valve replacement is an option when repair is not feasible [5]. Ine under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Summary of inclusion criteria for the structured literature review.
Item Inclusion criteria
Study design • Prospective randomised controlled trials
• Observational studies
(The only exclusion was single case studies.)
Population Adult patients (≥18 years) with MR, with a particular
focus on patients with severe MR
Interventions and
comparators
No restriction
Efﬁcacy outcomes • Treatment response rates (including molecular,
cytogenetic and haematologic responses)
• Time to and duration of response
• Overall survival
• Event free survival
• Progression-free survival
• Time to treatment failure
• Health-related quality of life
Safety/tolerability
outcomes
• Adverse events (all grades)
• Incidence of serious adverse events
Date • No restriction — search date March 5th, 2013
Abbreviations: MR, mitral regurgitation.
27J.-N. Trochu et al. / IJC Heart & Vasculature 5 (2014) 26–41asymptomatic MR watchful waiting may be employed unless the pa-
tient has signs of LV dysfunction, new onset atrial ﬁbrillation (AF) or
pulmonary hypertension, in which case surgery is considered [5]. In ex-
perienced surgical centres, mitral valve repair is considered reasonable
for asymptomatic patients with preserved LV function [7].
In patients with FMR, the management approach is not as clear as
operative mortality is higher than for OMR and long-term prognosis is
poorer [5]. Medical therapy plays a mandatory role in the management
of FMR [5]. In mild FMR there is no evidence to support surgical correc-
tion,whereas in severe FMR there is evidence to suggest surgerymay be
of use [5]. Shouldmedical therapy fail, extended HF treatment is consid-
ered (including cardiac resynchronisation, ventricular assist devices,
cardiac restraint devices, and heart transplantation) [5]. The impact of
surgery on survival in FMR is unclear as no RCTs have been performed
to provide deﬁnitive proof of beneﬁt. Valve repair is preferable in pa-
tients withmoderate ischaemicMRwho require coronary artery bypass
grafting (CABG) with moderate ischaemic MR and is considered in
selected patients when comorbidity is low [5]. In patients with symp-
tomatic severe FMR (despite optimalmedical therapy [including cardiac
resynchronization therapy]) and a high surgical risk, the European
Society of Cardiology (ESC) and the European Association for Cardio-
Thoracic Surgery (EACTS) guidelines suggest that the percutaneous mi-
tral clip procedure may be considered [5].
Determining the severity of MR is an important factor in the
management of the condition. According to the ESC/EACTS 2012 guide-
lines on the management of valvular heart disease, several approaches
can be used to determine MR severity. Such approaches include vena
contractawidth, proximal isovelocity surface area (PISA; for assessment
of the regurgitant volume [RVol] and effective regurgitant oriﬁce area
[EROA]), and ﬁnally, the integration of Doppler and morphological
information with cross-checks against the effects on LV, LA, and pulmo-
nary pressures [5]. Regurgitant jet area as a sole measure of severity is
not recommended by the ESC/EACTS due to reproducibility issues [5].
The American College of Cardiology/American Heart Association (ACC/
AHA) have also produced guidelines relating to MR which include
criteria for deﬁning mild, moderate, and severe MR [8].
It is important to establish the mortality and morbidity risks in
patients withMR as the development of LV dysfunction, pulmonary hy-
pertension and/or AF is often irreversible [6]. The current review con-
siders the medical/conservative management of MR and was designed
to assessmortality andmorbidity, and risk factors associated with func-
tional and organic MR of varying severity, with a focus on severe MR.
2. Methods
2.1. Structured literature review
A protocol was written to deﬁne all aspects of the structured litera-
ture review prior to commencement. Inclusion criteria are shown in
Table 1. Publications were restricted to English language, observational
and prospective studies; single case studies were excluded. The focus of
the current study was not the clinical effectiveness of preventative ap-
proaches; therefore, no restrictions were applied to interventions and
comparators.
2.2. Data extraction
Data sources used to identify published randomised controlled trials
(RCTs) were accessed March 5th, 2013 and included:
• MEDLINE in-Process; MEDLINE 1946 to present; Embase, 1974 to
present; Cochrane Library (Central Register of Controlled Trials, Data-
base of Systematic Reviews, Database of Abstracts of Reviews of Ef-
fects, and Health Technology Assessment Database).
• Hand-searching of conference proceedings (2010–2012): European
Congress of Cardiology and meetings of the Joint Working Groups ofthe European Society of Cardiology, Scientiﬁc Sessions of the
American Heart Association, Annual Meeting of the American College
of Cardiology, and the Heart Rhythm Society.
Structured search strings were adapted for each database as appro-
priate and included free text and Medical Subject heading (MeSH)
terms. Studies were screened on the basis of title/abstract against the
eligibility criteria. Data were extracted from eligible publications into
a predeﬁned table. Data collected included patient group, and out-
comes relating to disease progression, risk factors, mortality, survival,
hospitalisation, morbidity, and quality of life. Data are reported for
medically/conservatively managed patients unless otherwise stated.3. Results
3.1. Literature search results
A total of 4931 potentially relevant publications were identiﬁed
(after duplicate removal), of which 4846 were excluded on the basis
of title/abstract. On application of the inclusion criteria, 57 further pub-
lications were excluded. Four relevant publications were identiﬁed
through hand-searching. Therefore, 32 publications reporting on 31
unique studies satisﬁed the inclusion criteria (Fig. 1).
The number of identiﬁed unique studies (n= 32, represented by 30
publications) was nine in FMR [9–17], 17 in OMR (represented by
18 publications) [18–35], and ﬁve in a mixed population (MPMR)
[36–40]. Study and patient characteristics are summarised in Table 2.
The approach used to deﬁne of MR severity appeared to correlate with
recommendations from the ESC/EACTS and/or the ACC/AHA in four
FMR [9,10,12,16] and 15 (representing 14 studies) OMR [18–22,
24–26,29–35] and one MPMR [40] publications and was unclear/
unreported/no correlation in ﬁve FMR [11,13–15,17], three OMR [23,
27,28], and four MPMR [36–39] citations. The methodology used for
MR grading is shown in Table 2. Assessed using criteria from the ESC/
EACTS and the ACC/AHA guidelines [5,7] (where possible), publications
were categorised according to severity. In FMR, the majority of studies
considered MR of varying severity (mild to severe) [9–11,13–17]. In
one study it was assumed that the population primarily had severe
MR (based on means reported for RVol) [12]. In OMR, severity was pri-
marily severe in ten publications [20–22,24–26,28,29,34,35], moderate/
severe in three studies [23,27,31], and mild to severe in four studies
[18,30,32,33]. Finally, in MPMR, severity was mild to moderate [36],
28 J.-N. Trochu et al. / IJC Heart & Vasculature 5 (2014) 26–41moderate/severe [37], mild to severe [40] in one study each and severe
in two studies [38,39].
3.2. Outcomes
3.2.1. Mortality/survival associated with FMR
Mortality/survival outcomes in patients with FMR were reported in
nine publications [9–17].
All-cause mortality rates for MR vs no MR were reported in three
publications [10–12] (see Table 3).
Six publications demonstrated a relationship between increasing se-
verity of FMR and greater mortality risk [9–12,15,17]. For example, a
direct linear relationship between MR severity and one-year mortality
was observed in patients aged N70 years with FMR (ranging from
0% with no MR to 57% with Grade IV MR) [10]. The presence of moder-
ate/severe MR was the strongest independent predictor of death (odds
ratio [OR] 4.47 [95% CI 1.50–13.0], p = 0.006) [10]. A progressive rela-
tionship between increasing MR severity and greater mortality was
also noted in a large analysis of patients aged 16 to 90 years (mean
age 60 years) with systolic dysfunction and heart failure (HF) [15].
FMR was again an independent predictor of mortality in the analysis
(hazard ratio [HR] 1.23 [95% CI 1.13–1.34], p = 0.0001) [15]. Other
independent predictors of mortality included age, ischaemicFig. 1. Flow diagram of inclucardiomyopathy, diabetes, increasing New York Heart association
(NYHA class), LVEF (all p = 0.0001), ventricular gallop (p = 0.0407),
and male gender (p = 0.0048) [15].
An almost linear increase in the risk of death or heart transplant at
a mean of ﬁve year follow-up was observed in patients aged 21 to
90 years (mean age 59.6 years [±13.3]) with FMR and chronic
heart failure (CHF) [9]. Increased severity of FMR was strongly asso-
ciated with a greater risk of dying or requiring heart transplantation
(p = 0.0003) even after adjustment for potential confounders (such
as age, gender, NYHA class, and comorbidities). FMRwas classiﬁed as
either absent or as one of four progressive grades of severity, from
mild to severe (Grade I to Grade IV). The HR for Grade II was 1.44
(95% CI 0.90–2.31), p = 0.131; Grade III was 2.69 (95% CI 1.84–3.93),
p b 0.0001; and Grade IV was 3.58 (95% CI 2.31–5.52), p b 0.0001; all
compared with no FMR/Grade I [9]. Advancing age (p = 0.016), male
gender (p = 0.013), higher NYHA class (p = 0.002), AF (p = 0.048),
cardiac resynchronisation therapy (p = 0.002), and LVEF (per 10% in-
crease; p = 0.003) were all independent predictors of death or heart
transplant [9]. High mortality risk was also associated with severely re-
duced LVEF and severe MR in a Danish population of patients with HF
(HR of 1.17 [95% CI 1.03–1.26; p = 0.01] for each degree of increasing
MR severity with EF b 25%) [17]. Furthermore, death from all causes
was associated with a HR of 1.07 (95% CI 1.00–1.15; p = 0.04) forded/excluded studies.
Table 2
Characteristics of included studies.
Study Inclusion criteria Patient
characteristics
Number
enrolled
Severity of
MR, n (%)
Age, years
(SD)
Gender,
n (%)
LVEF %,
mean
(SD)
LVEDD (mm),
mean (SD)
LA dimension
(mm), mean
(SD)
Duration of
follow-up
Studies in FMR
Agricola [16]
Prospective
cohort study
Patients with systolic
dysfunction, EF b50%
and at least mild FMR
Patients with
ischaemic or
non-ischaemic
404 Moderate
to severe
58.8
(data not
reported
for mild)
Moderate
to severe
70.2 (10)
Moderate
to severe
Male (77.7)
Moderate
to severe
34.4 (10.8)
– – 4 years
Deﬁnition of MR severity: The severity of MR was graded with quantitative measurements using at least one of the following methods: (i) proximal isovelocity surface area analysed by the proximal ﬂow
convergence; (ii) VC width. MR was classiﬁed as mild, moderate or severe based on ERO area and VC width. Approach appeared to generally correlate with ESC/EACTS and ACC/AHA
recommendations [5,45]
Bursi [9]
Observational
cohort
Italy
Patients with systolic
dysfunction, EF b50%
and FMR
All patients
reported
systolic CHF and
FMR
469 No MR/Grade I
176 (37.5)
No MR/Grade I
Mean 60.5
(13.7)
No MR/Grade I
Male, 116
(63.9)
No MR/Grade I
32.3 (7.8)
No MR/Grade I
65.1 (8.3)
No MR/Grade I
43.0 (6.8)
≤10 yearsa
Grade II
87 (18.6)
Grade II
Mean 58.7
(12.0)
Grade II
Male, 56
(64.4)
Grade II
29.7 (7.9)
Grade II
69.4 (8.4)
Grade II
46.7 (7.9)
Grade III
142 (30.3)
Grade III
Mean 60.1
(14.3)
Grade III
Male, 99 (69.7)
Grade III
27.9 (7.6)
Grade III
70.3 (9.5)
Grade III
48.8 (7.3)
Grade IV
64 (13.6)
Grade IV;
Mean 56.9
(11.5)
Grade IV;
Male, 42 (65.6)
Grade IV;
26.1 (6.2)
Grade IV;
71.7 (9.8)
Grade IV;
51.1 (6.7)
Grade II
87 (18.6)
Grade II
Mean 58.7
(12.0)
Grade II
Male, 56 (64.4)
Grade II
29.7 (7.9)
Grade II
69.4 (8.4)
Grade II
46.7 (7.9)
Deﬁnition of MR severity: FMR was classiﬁed as either absent or as one of the four progressive degrees of severity from mild to more severe mitral regurgitation (Grade I through Grade IV). Approach appeared
to correlate with ESC/EACTS and ACC/AHA recommendations [5,45].
Ciofﬁ et al. [10]
Prospective
cohort study
Italy
Patients were included
if people were aged
N70 years with a
LVEF b 40% and a
diagnosis of CHF
Elderly patients
with FMR and
underlying systolic
CHF
175 Absent/mild MR
140
Absent/mild MR
Mean, 75 (5)
Absent/mild
MR
Female, 45 (32)
Absent/mild MR
30 (7)
– – 1 year
Moderate/severe
MR
35
Moderate/
severe MR
Mean, 77 (5)
Moderate/
severe MR
Female, 14
(39)
Moderate/severe
MR
27 (6)
– –
Deﬁnition of MR severity:MR severity was quantiﬁed in 5° using a 0–4+ grading system based on the value of maximal regurgitant jet area detected in the left atrium. Therefore MR was considered both as a
semi quantitative (5° from 0 to 4+) and dichotomous variable (moderate/severe MR = maximal regurgitant jet area ≥ 4.5 cm2). Similar approach to ACC/AHA practice guidelines [45] but
used a colour Doppler jet area b4.5 cm2 (as opposed to b4.0 cm2) to determine absent/mild MR; approach appeared to correlate with ESC/EACTS recommendations [5].
Deja et al. [11]
Retrospective
study of STICH
study RCT
Multi-country
Patients were included
if they have disease
amenable to CABG,
and had a LVEF of ≤35%
Patients with
ischaemic HF
1212 (599
patients
were
medically
treated)
No/trace MR
222 (medically
treated)
No/trace MR
Median, 59
(53–66)
No/trace MR
Male, 202 (91)
No/trace MR
Median, 30
(23–35)
– – Median
56 months
Mild MR
261
(medically treated)
Mild MR
Median, 59
(54–67)
Mild MR
Male, 226
(87)
Mild MR
Median, 27
(21–33)
– –
Moderate/severe
MR
116
(medically
treated)
Moderate/
severe MR
Median, 58
(53–67)
Moderate/
severe MR
Male, (83)
Moderate/severe
MR
Median, 25
(20–32)
– –
(continued on next page)
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Table 2 (continued)
Study Inclusion criteria Patient
characteristics
Number
enrolled
Severity of
MR, n (%)
Age, years
(SD)
Gender,
n (%)
LVEF %,
mean
(SD)
LVEDD (mm),
mean (SD)
LA dimension
(mm), mean
(SD)
Duration of
follow-up
Deﬁnition of MR severity: This study elected to use the site-reported assessment of MR severity to group patients for analysis. The baseline case report form permitted the baseline MR grade to be characterised
by the site study investigators as none or trace, mild, moderate, severe, or not assessed. Correlation with ECS/EACTS and ACC/AHA recommendations was unclear [5,45].
Grigioni et al. [12]
Observational
cohort study
US
Patients with a history
of MI older than 16 days
before baseline
assessment
Patients were all
post MI,
comorbidities
deﬁned as a
comorbidity index.
303 Assumed
primarily severe
based on mean
RVol
(36 ± 24 mL/
beat) and LV/LA
enlargement
Patients with
MR = 194
(64)
Assumed severe
Mean, 71 (11)
Assumed severe
Male, 135 (70)
Assumed severe
33 (14)
Assumed severe
33 (5)
(mm/mm2)
Assumed
severe
27 (7)
(mm/mm2)
817 patients years
Deﬁnition of MR severity: The degree of MR was determined by quantitative Doppler in 30 patients, by the PISA method in 146, and by both techniques in 18. Approach appeared to correlate with ESC/EACTS
recommendations [5]; unclear whether there was correlation with the ACC/AHA recommendations [45].
Koelling et al. [13]
Retrospective
database analysis
US
Patients were eligible
for inclusion if they
had undergone
echocardiography
between 1995 and 1998
Patients had a LVEF
of ≤35% with
mitral/tricuspid
regurgitation.
1436 None/mild MR
737
None/mild MR
Mean, 60.2
(14.5)
None/mild MR
Female, (30.1)
None/mild MR
21 (5)
– None/mild MR
45 (9)
Mean of
369 ± 368 days
across all
severity
groups
Moderate MR
427
Moderate MR
Mean, 63.1
(14.7)
Moderate MR
Female,
(33.9)
Moderate MR
20 (5)
– Moderate MR
48 (8)
Severe MR
272
Severe MR
Mean, 63.1
(14.4)
Severe MR
Female,
(35.6)
Severe MR
19 (5)
– 51 (8)
Deﬁnition of MR severity: The maximum jet area in any view was considered to represent the severity of MR. Attention was paid to eccentricity of jet orientation and the severity assessed in this light. Severe
MR: MR jet encompassed N50% of the left atrial area. Approach did not appear to correlate with ESC/EACTS and ACC/AHA recommendations [5,45].
Pecini et al. [17]
Prospective
cohort study
Patients hospitalised
for symptoms and
clinical signs of HF
and assessed for MR
Patients with HF
with/without MR
3078 No/trace MR
1890 (61.4)
No/trace MR
75 (range
52–89)
No/trace MR
Male, (60)
No/trace MR
45 (range
17–60)
No/trace MR
–
No/trace MR
–
Median
4.5 years
Mild MR
628 (20.4)
Mild MR
75 (range
53–89)
Mild MR
Male, (67)
Mild MR
34
(range 15–60)
Mild MR
–
Mild MR
–
Moderate MR
452 (14.7)
Moderate MR
75 (range
53–89)
Moderate MR
Male, (59)
Moderate MR
30 (range
13–60)
Moderate MR
–
Moderate MR
–
Severe MR
108 (3.5)
Severe MR
75 (range
54–89)
Severe MR
Male, (51)
Severe MR
34 (range
13–60)
Severe MR
–
Severe MR
–
Deﬁnition of MR severity: The local investigators were not required to report the methods they used for the estimation of MR. The most frequently used methods at the time were the extent of the MR regurgitant
jet and the vena contracta on the colour ﬂow modality from two-dimensional views. Unclear whether approach correlates with ESC/EACTS and ACC/AHA recommendations [5,45]
Rossi et al. [14]
Prospective
cohort study
Italy
Patients with chronic
HF due to dilated
cardiomyopathy, with
structurally normal MV
Patients with HF,
both ischemic and
non-ischemic dilated
cardiomyopathy
1256 No MR
339
No MR
Mean, 65 (11)
No MR
Female, (20)
No MR
34 (8)
No MR
61 (7)
– Mean
2.7 ± 2 years
Mild/moderate
616
Mild/
moderate
Mean 68 (10)
Mild/moderate
Female, (22)
Mild/moderate
33 (8)
Mild/moderate
63 (8)
–
Severe MR
301
Severe MR
Mean, 69 (11)
Severe MR
Female,
(20)
Severe MR
29 (8)
Severe MR
66 (9)
–
Deﬁnition of MR severity: Evaluation of FMR assessed by measuring vena contracta (VC) or regurgitant volume (RVol) or ERO:
- Severe FMR: Mitral RVol N30 mL or ERO N0.2 cm2 or VC width N0.4 cm
- Mild/moderate FMR: Mitral RVol ≤ 30 mL or ERO ≤ 0.2 cm2 or VC width b =0.4 cm
(continued on next page)
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Table 2
Study Inclusion criteria Patient
characteristics
Number
enrolled
Severity of
MR, n (%)
Age, years
(SD)
Gender,
n (%)
LVEF %,
mean
(SD)
LVEDD
(mm),
mean (SD)
LA dimension
(mm), mean
(SD)
Duration of
follow-up
Approach did not
appear to correlate
with ESC/EACTS and
ACC/AHA
recommendations [5,45].
Trichon et al. [15]
Prospective
database analysis
US
Patients with a
LVEF of b40%
were included
All patients
underwent
evaluation for clinical HF
with NYHA
2057 No MR
901 (43.8)
No MR
Median, 60
(51–68)
No MR
Male,
(71.1)
No MR
Median, 28
(22–34)
– – Median
3.7 years
(1.7–7.2)
Grades I–II
811 (39.4)
Grades I–II
Median, 62
(53–69)
Grades I–II
Male,
(59.7)
Grades I–II
Median, 25
(19–32)
– –
Grades III–IV
345 (16.8)
Grades III–IV
Median, 65
(55–72)
Grades III–
IV
Male,
(49.3)
Grades III–IV
Median, 25
(20–33)
– –
Deﬁnition of MR severity: The degree of MR was graded visually by the following criteria: 0) no systolic regurgitation of contrast into the left atrium; 1) minimal regurgitation that cleared rapidly with a
subsequent beat; 2) moderate opaciﬁcation of the left atrium that cleared within several beats; 3) Intense opaciﬁcation of the left atrium that became equal to that of the left ventricle; 4) dense opaciﬁcation
of left atrium to a greater degree than the left ventricle, with reﬂux of contrast material into the pulmonary veins. Approach did not appear to correlate with ESC/EACTS and ACC/AHA recommendations [5,45].
Studies in OMR
Arias et al. [31]
Prospective cohort
Argentina
Asymptomatic patients
aged N18 years
Patients had at
least moderate,
organic MR (ERO
≥0.20 cm2)
144 Moderate/
severe
144 [105 (73%)
had severe MR
(ERO
≥0.40 cm2)]
Moderate/
severe
71 (12)
Moderate/
severe
Female,
95 (66)
Moderate/
severe
66 (4.8)
Moderate/
severe
52.3 (5.9)
– Median,
7 months
Deﬁnition of MR severity: The degree of MR was quantiﬁed according to ERO using doppler and two-dimensional echocardiography. ERO was calculated as the average of the quantitative measurement and the
proximal isovelocity surface area method. Quantitative measurement was performed by measuring volumetric ﬂow through the mitral valve in diastole in comparison with a measure of forward stroke volume
measured at the LV outﬂow tract in systole. Severe MR deﬁned as EROA ≥0.40 cm2; moderate MR deﬁned as ERO ≥0.20 cm2. Approach appeared to correlate with ESC/EACTS and ACC/AHA
recommendations [5,45].
Detaint et al. [33]
Prospective cohort
US
Patients without
previous valve
repair/replacement
enrolled between 1996
and 1998
Patients with chronic,
organic MR
124 Mild to severe
Mild (30%)
Moderate
(34%)
Severe (35%)
Mild to
severe
63 (13)
Mild to
severe
75 (60)
Mild to severe
69 (8)
– – 5 years
Deﬁnition of MR severity: MR was quantiﬁed using three methods: (i) quantitative Doppler with mitral and aortic stroke volumes; (ii) quantitative 2D echocardiography with LV stroke volumes; (iii) proximal
isovelocity surface area method. Mild MR (RF b30%); moderate MR (RF 30–49%); severe MR (RF ≥50%). Approach appeared to correlate with ESC/EACTS and ACC/AHA recommendations [5,45].
Enriquez-Sarano
et al. [18]
Retrospective
analysis of a
prospective cohort
US
Patients with at least
mild MR (1991–2000)
quantitatively assessed
by at least two methods.
Patients with
asymptomatic OMR
456 Mild MR,
ERO b20 mm2
129
Mild MR, ERO
b20 mm2
64 (14)
Mild MR,
ERO
b20 mm2
Male (31)
Mild MR, ERO
b20 mm2
68 (9)
Mild MR, ERO
b20 mm2
49 (4)
– 2.7 ± 2.9 years
Moderate,
ERO 20–
39 mm2
129
Moderate,
ERO
20–39 mm2
65 (14)
Moderate,
ERO
20–
39 mm2
Male (64)
Moderate, ERO
20–39 mm2
70 (8)
Moderate,
ERO
20–39 mm2
54 (6)
–
Severe MR,
ERO ≥40 mm2
198
Severe MR,
ERO
≥40 mm2
61 (14)
Severe MR,
ERO
≥40 mm2
Male (82)
Severe MR,
ERO
≥40 mm2
70 (8)
Severe MR,
ERO
≥40 mm2
61 (6)
–
(continued on next page)
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Table 2 (continued)
Study Inclusion criteria Patient
characteristics
Number
enrolled
Severity of
MR, n (%)
Age, years
(SD)
Gender,
n (%)
LVEF %,
mean
(SD)
LVEDD
(mm),
mean (SD)
LA dimension
(mm), mean
(SD)
Duration of
follow-up
Deﬁnition of MR severity: Mild MR corresponds to an ERO N20 mm2. Moderate MR corresponded to an ERO b30 to 59 mL per beat, and an ERO b20 to 39 mm2. Severe MR corresponded to an ERO ≥60 mL per
beat and, an ERO ≥40 mm. The severity of MR was also qualitatively classiﬁed in grades (1/4 to 4/4). Approach appeared to correlate with ESC/EACTS and ACC/AHA recommendations [5,45].
Enriquez-Sarano
et al. [19]
Prospective
observational
cohort
US
Patients were included
if they had conﬁrmed
MR, echocardiography
Patients with OMR with at
least mild MR at baseline
74 Mild to severe
74
(severe = 33)
Mild to
severe
60 (14)
Mild to
severe
Female
(35)
Mild to severe
66 (7)
Mild to
severe
112 (29)
(mL/mm2)
– Mean
1.5 ± 1.2
years
Deﬁnition of MR severity: The degree of MR was assessed with at least two of three methods— Quantitative Doppler, quantitative two-dimensional echocardiography, proximal isovelocity surface area. Diagnosis of
OMR was based on the presence of intrinsic mitral valve lesions demonstrated by two-dimensional echocardiography. Severe MR RVol ≥60 mL. Approach appeared to correlate with ESC/EACTS and ACC/AHA
recommendations [5,45].
Grigioni et al. [20]
Retrospective
cohort
(2 population
data sets)
US
2 populations
1) Patients were
eligible if they had
OMR (ﬂail leaﬂet) and
were in sinus rhythm
at baseline.
2) Patients had MVP diagnosed
between
1989–95
1) Majority of
patients had severe
MR (based on EF)
and ﬂail leaﬂet.
2) Patients had
severe MR with
MVP
Assumed
severe
1) 468
(360
eligible)
2) 645
Assumed severe
1) 360
2) 89
Assumed
severe
1) 65 (13)
2) 67 (17)
Assumed
severe
Male,
1) (74)
2) (56)
Assumed severe
1) 64 (9)
2) 61 (1)
Assumed
severe
1) 35 (6)
2)–
Assumed severe
1) 50 (8)
2) 46 (10)
Mean, 38 ± 40
months
Deﬁnition of MR severity:
1) Severity of MR was assessed semi quantitatively on a scale of 1 to 4 by Doppler echocardiography.
Diagnosis of ﬂail leaﬂets was based on failure of leaﬂet coaptation, with rapid systolic movement of the ﬂail segment into the LA.
2) MR grade was reported at 3 or 4/4 by standard Doppler methods. All subjects had comprehensive Doppler and colour-ﬂow imaging examination. Diagnosis of MVP was based on current criteria, using
long-axis views of the valve.
Approach appeared to correlate with ESC/EACTS and ACC/AHA recommendations [5,45].
Grigioni et al. [21]
Retrospective
database analysis
Europe
(France, Italy)
Patients were included
if they had conﬁrmed
ﬂail leaﬂet at study entry
Patients had severe
OMR with ﬂail
leaﬂet.
394 Primarily severe
MR Grades
III–IV; 381
(97%)
Primarily
severe
64 (11)
Primarily
severe
Male, 265
(67)
Primarily
severe
67 (10)
Primarily
severe
59 (8)
Primarily severe
48 (8)
Mean
4.6 ± 3.1
years
Deﬁnition of MR severity: Severity of MR was assessed semi quantitatively on a scale from 1 to 4 by Doppler echocardiography. Assumed to correlate with ACC/AHA practice guidelines [45]. Approach appeared
to correlate with ESC/EACTS and ACC/AHA recommendations [5,45].
Kang et al. [22,35]
Observational
cohort
Korea
Patients considered
eligible for surgical
intervention with severe
MR due to MV prolapse
or ﬂail leaﬂet
Asymptomatic
patients with
organic severe MR
due to MV prolapse
and/or ﬂail MV
Kang, 2012
Severe
815
(525 medical
management)
Kang, 2012
Severe
815
Kang, 2012
Severe
47 (15)
Kang, 2012
Severe
Male, 430
– – Kang, 2012
Severe
35 (4)
10 years
Kang, 2009
Severe
447
Kang, 2009
Severe
447
Kang, 2009
Severe
50 (15)
Kang,
2009
Severe
Male, 253
– – – 7 years 2009
Severe
Deﬁnition of MR severity: With the simpliﬁed proximal isovelocity surface area (PISA) method, the degree of MR was graded as mild (PISA radius b4 mm), moderate (PISA radius b8 mm), or severe (PISA radius
≥8 mm). Approach appeared to correlate with ESC/EACTS and ACC/AHA recommendations [5,45].
Kim et al. [32]
Prospective cohort
Japan
Patients with MVP
(but not congenital/
rheumatic heart disease,
CAD, or cardiomyopathy)
referred to hospital
between April 1986
and August 1993
Patients with congenital/
rheumatic heart disease,
CAD, or cardiomyopathy
were excluded
229 No/trivial 17
(7)/45 (20)b
50.8
(14–88)
Male, 105 – – – Approx. 80
months
Mild
83 (36)b
Moderate;
50 (22)b
Severe
34 (15)b
32
J.-N
.Trochu
etal./IJC
H
eart
&
V
asculature
5
(2014)
26
–41
Deﬁnition of MR severity: Examined using Colour Doppler echocardiography. Severity assessed in terms of the distance in the left atrium reached by regurgitant ﬂow from the mitral valve oriﬁce, the maximum
regurgitant jet area expressed as a percentage of the left atrial area, and the proximal isovelocity surface area visible in any view. Approach appeared to correlate with ESC/EACTS and ACC/AHA recommendations [5,45].
Le Tourneau et al. [30]
Prospective cohort
US
Patients with papillary
muscle rupture,
associated mitral valve
stenosis of any degree,
associated aortic or
congenital heart disease
or previous valvular
surgery were excluded.
Patients with at
least mild, organic
MR and in sinus
rhythm at baseline
492 Mild
110 (22)
62 (15) Male,
296 (60)
69 (8) 56 (8) 55 (26) 5 years
Moderate
110 (22)
Severe
272 (56)
Deﬁnition of MR severity: MR was quantiﬁed by at least 2 of 3 validated methods, averaged to calculate RVol and ERO. Methods used were the proximal-isovelocity-surface-area method in 391 patients,
quantitative Doppler method (using mitral and aortic stroke volumes) in 485 and quantitative 2-dimensional method (using LV volumes and aortic stroke volume) in all patients. Because ERO was not
measurable in 32 patients, RVol, which has similar prognostic value as ERO and was consistently measurable in all patients, was used as a measure of MR severity (Mild MR, b30 mL/beat; Moderate MR,
30–59 mL/beat; Severe MR, ≥60 mL/beat). Approach appeared to correlate with ESC/EACTS and ACC/AHA recommendations [5,45].
Ling et al. [23]
Retrospective
Observational
cohort
US
Patients were eligible
if they had ﬂail leaﬂet,
and had been diagnosed
with echocardiography
between 1980 and 1989.
All patients had
ﬂail leaﬂet. A total
of 188 (82%) had
a history of apical
cardiac murmur or
cardiac symptoms
for ≥3 months
229 Moderate/
severe
(grade 3/4)
197 (87)
All patients
65.5 (13)
All
patients
Male, 161
(70)
All patients
65 (9)
All patients
34 (5)
(mm/mm2)
All patients
29 (6)
(mm/mm2)
10 years
Deﬁnition of MR severity: Not explicitly stated but grade 3+ or 4+ was assumed to be moderate/severe. Unclear whether there was correlation with the ESC/EACTS and the ACC/AHA recommendations [5,45].
Montant et al. [24]
Retrospective
database analysis.
Belgium
Patients with severe
MR ≥ grade 3 diagnosed
between 1990 and 2001.
Patients with
asymptomatic
severe OMR
192 Severe MR
(medically
managed)
67 (medically
managed)
Severe MR
(medically
managed)
64 (15)
Severe MR
(medically
managed)
Male (69)
Severe MR
(medically
managed)
71 (7)
Severe MR
(medically
managed)
55 (7)
–
Severe MR
(medically
managed)
47 (8)
Median,
8.5 years
Deﬁnition of MR severity: Severity assessed semi quantitatively on a scale of 1+ to 4+ by an integrated approach that included valve morphology, the size of the regurgitant jet in the left atrium, the proximal
regurgitant jet width, and pulmonary venous ﬂow pattern. Approach appeared to correlate with ESC/EACTS and ACC/AHA recommendations [5,45].
Pizzarro et al. [34]
Prospective cohort
Argentina
Patients with normal
LV performance
(EF N60%)
Patients with severe,
asymptomatic organic MR
167 Severe,
derivation
cohortc
63 (7) Male, (63) 67 (5) – – 36 (8) months
102 Severe,
validation
cohortc
66 (8) Male, (63) 66 (5) – – 31 (9) months
Deﬁnition of MR severity: quantiﬁed using classical Doppler parameters. RVol, regurgitant fraction and ERO (as an average of the quantitative method, and the proximal isovelocity area method) were assessed.
Approach appeared to correlate with ESC/EACTS and ACC/AHA recommendations [5,45].
Rosen et al. [28]
Prospective cohort
US
Patients were selected
and entered into a prospective study if
they had non-ischemic
MR and were asymptomatic/
minimally symptomatic.
Patients had severe
MR (not-ischemic
MR) and were either
asymptomatic or minimally
symptomatic.
60 Severe MR
31
Severe MR
51 (13)
Severe MR
Male, 19
(61)
Severe MR
57 (6)
– Severe MR
50 (10)
Mean
4.7 ± 4.7 years
Deﬁnition of MR severity: Not reported.
Rosenhek et al. [25]
Prospective cohort
study
Austria
Patients with severe
MR diagnosed by
echocardiography.
Patients with severe OMR; ﬂail leaﬂet
and mitral valve prolapse
132 Total
population
severe
132 (100)
Flail leaﬂet
severe
58
Total
population
severe
55 (15)
Flail leaﬂet
severe
57 (12)
Total
population
severe
Female,
(37)
Flail leaﬂet
severe
Female,
(23)
Total
population
severe
66 (5)
Flail leaﬂet
severe
67 (6)
Total
population
severe
56 (6)
Flail leaﬂet
severe
56 (6)
Total population
severe
60 (10)
Flail leaﬂet severe
62 (10)
Median 69.2
months (range
41.8–81.3)
Deﬁnition of MR severity : Severe MR: A ﬂail leaﬂet with clearly visible coaptation defect was considered a deﬁnite sign of severe MR. In patients with prolapse without ﬂail, a proximal jet width 6 mm and a ﬂow
convergence radius 7 mm at a Nyquist limit of 55 to 65 cm/s were considered speciﬁc signs of severe MR. LV enlargement with normal LV function in the absence of any causes of LV dilatation other than
MR was considered supportive of severe MR. In case of uncertainty, pulmonary venous ﬂow was studied, and holosystolic ﬂow reversal was then considered a speciﬁc sign of severe MR. Approach appeared to
correlate with ESC/EACTS and ACC/AHA recommendations [5,45].
(continued on next page)
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Table 2 (continued)
Study Inclusion criteria Patient
characteristics
Number
enrolled
Severity of
MR, n (%)
Age, years
(SD)
Gender,
n (%)
LVEF %,
mean
(SD)
LVEDD
(mm),
mean (SD)
LA dimension
(mm), mean
(SD)
Duration of
follow-up
Rusinaru et al. [26]
Retrospective
database analysis
EU/US
Consecutive patients
identiﬁed with MR
due to ﬂail leaﬂet
Patients from the
MIDA database
with OMR due to
ﬂail leaﬂet
788 Severe MR
(91)
Total
population
64.1 (12.5)
Total
population
Male, 546
(69.3)
Total
population
65.9 (9.2)
Total
population
59.3 (7.2)
Total population
47.7 (8)
Mean
6.2 ± 3.9
years
Deﬁnition of MR severity: Severity of MR was assessed semi quantitatively on a scale from 1 to 4 by Doppler echocardiography. Approach appeared to correlate with ESC/EACTS and ACC/AHA recommendations [5,45].
Singh et al. [29]
Case–control study
USA
Patients with isolated,
pure severe MR due to
primary MVP
Severe MR due to
MVP
54 All patients
reported severe
MR
Male, 57
(11)
Female, 56
(13)
Male, 33 – Male, 67 (7)
Female, 61
(6)
Male, 53 (8)
Female, 49 (9)
11 years
Patients with
uncomplicated MVP
(similar to MVP patients
in society)
MVP without MR 117 No MR Male, 35
(16)
Female, 36
(14)
Male, 40 – Male, 52 (6)
Female, 48
(4)
Male, 36 (4)
Female, 30 (2)
Deﬁnition of MR severity: Pulsed and/or colour ﬂow Doppler echocardiography and/or left ventriculography. Severe MR deﬁned as ≥3+/4+. Approach appeared to correlate with ESC/EACTS and ACC/AHA
recommendations [5,45].
Steptoe et al. [27]
Retrospective
database analysis
UK
Patients with dilated
cardiomyopathy
Patients with MR
details were
identiﬁed among
the patient
population.
106 Moderate/
severe
19 (31.6)d
Total
population
47.6 (14.4)
Total
population
Male, (40)
– Total
population
54.5 (9.3)
– Approx. 1 year
Deﬁnition of MR severity: Details of MR and other baseline characteristics were obtained from clinical records. Unclear whether there was correlation with the ESC/EACTS and the ACC/AHA recommendations [5,45].
Studies in functional and OMR (mixed population)
Bach et al. [40]
Retrospective
review
US
Patients included in the
University of Michigan
Echocardiography
Laboratory database
Adult patients with
moderate-to-severe
or severe organic
MR documented
on any
echocardiogram
during 2005e
118 (FMR) All patients had
severe or
moderate-
to-severe MR
53.0 (15.9) 51 (60) 25.6 (16.5) 66.3 (12.5)
(left
ventricular
internal
diameter
in diastole)
50.9 (8.2) 776 days
(0–1225 days)
112 (OMR) 59.8 (17.2) Male, 63
(56)
58.6 (11.4) 52.2 (8.0)
(left
ventricular
internal
diameter
in diastole)
49.4 (7.6)
Deﬁnition of MR severity: Echocardiographic analysis based on overall clinical assessment using all available echocardiographic and Doppler criteria, including colour-ﬂow Doppler jet size, jet eccentricity,
characteristics of the proximal ﬂow convergence zone, and jet duration. A semiquantitative system of none, trivial, mild, mild-to-moderate, moderate, moderate-to-severe, and severe was used. Signiﬁcant MR
was deﬁned as moderate-to-severe or severe. Approach appeared to correlate with ESC/EACTS and ACC/AHA recommendations [5,45].
Baskett et al. [36]
Retrospective
study of SOLVD
study (sub-study)
Canada
Patients were eligible
if they were aged
21–80 year, with an
EF ≥35%
Patient with MR
and left ventricular
dysfunction
259 Mild to
moderate,
Grades I–III
39
Mild to
moderate,
Grades I–III
58 (11)
Mild to
moderate,
Grades I–
III
Female,
(13)
Mild to
moderate,
Grades I–III
0.27 (0.06)
– – Mean 41 ± 7
months
Deﬁnition of MR severity:Mitral insufﬁciency (absent, grade 1, grade 2, grade 3 and grade 4). No grade 4 mitral insufﬁciency was reported. Unclear whether there was correlation with the ESC/EACTS and the
ACC/AHA recommendations [5,45].
Conti et al. [37]
Retrospective
database analysis
US
Patients with grade
III–IV MR awaiting a
heart transplant
Patients eligible for
a heart transplant
with severe MR
23 Mild to severe,
Grades I–IV
Early death
Male, n = 10
Late death
Male, n = 8
Late transplant
Male, n = 5
Early death
40 (19)
Late death
55 (7)
Late
transplant
57 (8)
Early
death
Male,
n = 6
Late death
Male,
n = 8
Late
Early death
19 (4)
Late death
19 (4)
Late transplant
20 (9)
– – –
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Male,
n = 5
Deﬁnition of MR severity: Not reported. Unclear whether there was correlation with the ESC/EACTS and the ACC/AHA recommendations [5,45].
Delahaye et al. [39]
Retrospective
analysis
France
Patients with severe
MR admitted to hospital
between January 1980
and December 1987
Patients who
underwent surgery
162 All patients
classiﬁed as
severe MR
59.5 (12.1) Male, 85
(52.4)
– 40.2 (9.7) – 3.9 (2.5) years
Patients not
undergoing surgery
54 59.0 (18.9) Male, 37
(70.4)
– 42.4 (9.3) – 3.5 (2.7) years
Subset of patients
not undergoing
surgery considered
as not yet surgical
candidates
32 55.4 (8.2) Male, 22
(68.7)
– 37.7 (6.6) –
Deﬁnition of MR severity: Deﬁnition of severe MR was primarily clinical. Patients considered as having severe MR, if they were referred by their attending cardiologist for investigation to decide if surgery
should be imminent. Patients were included if systolic murmur intensity was over 3/6, and/or S3 gallop was present; cardiothoracic ratio was over 0.50; left atrial diameter at echocardiography was N45 mm.
Approach did not appear to correlate with ESC/EACTS and ACC/AHA recommendations [5,45]
Mirabel et al. [38]
Retrospective
observational
study
European
(multicentre)
Patients ≥18 years who
met echo-cardiographic
requirements
Patients with
symptomatic severe
MR denied surgery
877 (396
with
severe MR)
Severe MR,
non-surgery
193
Severe MR,
non-surgery
69 (13)
Severe MR,
non-
surgery
Male, 90
(46.6)
Severe MR,
non-surgery
48 (16)
Severe MR,
non-surgery
57 (8)
Severe MR,
non-surgery
49 (10)
1 year
Deﬁnition of MR severity:MR severity was assessed using Doppler echocardiography. Severe MR, grade 3/4 as previously reported by Iung et al. 2003 [46]. Unclear whether there was correlation with the
ESC/EACTS and the ACC/AHA recommendations [5,45].
BNP, brain natriuretic peptide; CABG, coronary artery bypass graft; CHF, congestive heart failure; EF, ejection fraction; ERO, effective regurgitant oriﬁce; FMR, functional mitral regurgitation; HF, heart failure; LA, left atrium; LV, left ventricle; LVEDD,
left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction;MI, myocardial infarction; MIDA,mitral regurgitation international; MR,mitral regurgitation;MV,mitral valve;MVP,mitral valve prolapse; RVol, regurgitant volume; RCT,
randomised controlled trial; SD, standard deviation; VC, vena contracta.
a Patients were followed from 1997 to 2007. Unless they underwent a heart transplant, died or moved out of the study area.
b Of the 147 patients with a prolapsed anterior leaﬂet, the grade of MR ranged from none to mild in 110 (75%) and from moderate to severe in 37 (25%). However, moderate-to-severe regurgitant ﬂow was present in 36 (61%) with a prolapsed
posterior leaﬂet, compared with trivial to mild MR present in 23 (39%) patients. Among patients with prolapse of both leaﬂets, 11 (48%) hadmoderate-to-severe regurgitant ﬂow. The incidence of moderate and severe MRwas signiﬁcantly higher in
patients with a prolapsed leaﬂet compared with patients with a prolapsed anterior leaﬂet.
c Applying a splitting technique, the ﬁrst 167 consecutive patients were analysed as the derivation cohort and the next 102 consecutive patients as the validation set.
d Complete questionnaires returned by 60 patients with moderate/severe MR reported in 31.6% (calculated to be n = 19).
e Details not reported for each treatment group, data are for all enrolled.
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36 J.-N. Trochu et al. / IJC Heart & Vasculature 5 (2014) 26–41each degree of increasing MR (after adjustment for confounders) and
mortality risk was highest among patients with the greatest severity
of MR [17].
In patients who had a history of myocardial infarction (MI; N16
days), the degree of MR was directly related to mortality risk [12].
In such patients, an effective regurgitant oriﬁce (ERO) ≥20 mm2 was
considered to indicate MR of greater severity and was associated with
a greater risk of mortality in comparison to patients without MR
(adjusted RR 2.23 [95% CI 1.31–3.79], p = 0.003) [12]. A higher
regurgitant volume (RVol ≥30 mL) was also associated with higher
mortality in comparison to patients with MR and a RVol b30 mL (65%
[±7] vs 56% [±9] at 5 years, respectively, p b 0.001; RR per 10 mL
RVol increase 1.13) [12]. The inﬂuence of ERO on mortality was greater
than that of RVol as ERO remained an independent predictor of excess
mortality (p = 0.017) in multivariate analysis whereas RVol did not
(p=0.13) [12]. In another publication that demonstrated a strong asso-
ciation withMR severity at baseline andmortality [11], the study popu-
lation was medically managed patients with coronary artery disease
(CAD) and an ejection fraction (EF) ≤35% from the STICH trial (mild
MR: HR 1.54 [95% CI 1.14–2.07]; moderate to severe MR: HR 2.01 [95%
CI 1.42–2.85]; all vs no MR) [11]. It can be assumed from data provided
in the aforementioned six publications that severe FMR is associated
with a greater mortality risk than lower grades of severity.
Severe FMR was associated with a greater mortality risk in compar-
isonwith noMR in three studies [13,14,17]. Koelling et al. demonstrated
that severeMRwas associatedwith an 84% increased risk of death vs no
MR in patientswith left ventricular systolic dysfunction (LVSD) (RR 1.84
[95% CI 1.43–2.38]) [13]. In patients with HF due to ischaemic and non-
ischaemic dilated cardiomyopathy (mean age 67 [±11]), Rossi et al.
observed an increased risk of all-cause mortality with severe FMR (HR
1.5 [95% CI 1.2–2.1], p = 0.009) [14]. Rossi et al. also reported other
independent predictors of mortality such as presence of cancer (HR
2.17 [95% CI 1.56–3.03], p b 0.0001), CAD (HR 2.04 [95% CI 1.60–2.61],
p b 0.0001), heart rate (beats per minute; HR 1.01 [95% CI 1.01–1.02],
p b 0.0001), or LVEF (% HR 0.98 [95% CI 0.96–1.00], p b 0.00254) [13].
Patients with HF were also considered by Pecini et al. [17]. The study
demonstrated that in those with a LVEF b25% (but not ≥25%), severe
MR was associated with a signiﬁcantly greater mortality risk then no/
trace MR (HR 1.78, 05% CI 1.09–2.89; p = 0.02) [17]. Agricola et al.
and Bursi et al. have also reported data that severe MR in patients
with LV dysfunction is a strong predictor of mortality [9,16]. It is clear
that patients with severe MR are at a greater mortality risk than their
peers with no MR.Table 3
Mortality (total or all-cause) in FMR.
With FMR Without FMR p value
One-year mortality
Ciofﬁ et al. [10]a
Grade I: 7%
Grade II: 15%
Grade III: 45%
Grade IV: 57%
0% 0.00001
Five-year mortalityb
Grigioni et al. [12]c
All: 62% (±5)
ERO b20 mm2: 53% (±8)
ERO ≥20 mm2: 71% (±9)
39% [±6] b0.001
Deja et al. [11]d
Mild: 44%
Moderate/severe: 50%
32%e NR
Abbreviations: CABG, coronary artery bypass graft; CAD, coronary artery disease; ERO, ef-
fective regurgitant oriﬁce; HF, heart failure; MR, mitral regurgitation; NR, not reported.
a Elderly patients with systolic chronic HF.
b Median 56 months in Deja et al. [11].
c Total mortality in post-MI patients with ischaemic MR.
d Patients with CAD amenable to CABG and LVER ≤ 35%.
e None/trace MR.Two publications reported results regarding the impact of cardiac
death on reported mortality [9,12]. Cardiac death did not appear to be
the cause of excess mortality with increasing severity of MR in one
study [9]. In a second publication, Grigioni et al. found that the ischae-
mic (i.e. functional) MR (after MI) was associated with excess mortality
(univariate relative risk [RR] 2.32 [95% CI 1.56–3.52]) due to a higher in-
cidence of cardiac death (RR 2.30 [95% CI 1.47–3.72]) vs no MR [12].
In publications reporting survival rates, a decrease with increasing
MR severity was observed in seven publications [9,10,12–16]. Koelling
et al. reported that survival in patients with LVSD was inversely related
with MR grade (one-year and three-year survival rates: absent/mild,
73.8% [±1.9] and 57.9% [±2.9]; moderate, 70.6% [±2.5] and 50.2%
[±3.6]; severe, 59.3% [±3.4] and 34.7% [±5.1]) [13]. However, there
was no signiﬁcant difference in overall one-year survival rates with
mild MR and no/trace MR (72.9% [±2.4] vs 74.2% [±3.1]) [13]. De-
creased survival associated with increasing MR severity was also
noted by Agricola et al., Ciofﬁ et al., and Trichon et al. [10,15,16]. In
patientswith LV systolic dysfunction, Agricola et al. reported 4-year sur-
vival free of all-causemortality at 64%, 50%, and 49% for mild, moderate,
and severe MR, respectively [16]. Survival free of cardiac death also de-
creasedwith increasingMR severity (mild: 94%,moderate; 57%; severe:
55%) [16]. According to Ciofﬁ et al., survival in patients aged N70 years
with FMR was 90% and 51% in absent/mild and moderate/severe MR
groups, respectively, [10]. Trichon et al. reported lower survival rates
at one, three, and ﬁve years in patients with moderate/severe MR
(72.9%, 51.4%, 39.9%, respectively) vs mild (84.4%, 62.3%, 48.7%, respec-
tively) or no MR (87.6%, 71.8%, 54.2%, respectively) (p b 0.001) [15].
Overall survival free of hospitalisation for worsening HF decreased
with increasing FMR severity in one publication (no MR, 40%; mild/
moderate MR, 25%; severe MR, 7% [mean follow-up: 2.7 years ±2])
[14]. A further publication demonstrated that survival free of HF at 4
years was lowest for patients with severe MR (18% vs 20% [moderate]
and mild [62%]) [16]. Moderate to severe FMR was a strong prognostic
indicator of HF [16]. In patients with underlying HF, ﬁve-year
transplant-free survival was also shown to decrease with increasing
MR severity (no MR/Grade I, 82.7% [3.1]; Grade II, 58.5% [4.6]; Grade
IV, 46.5% [6.7]; p b 0.0001) [9].
Finally, Grigioni et al., 2001 found that after MI, ischaemic MR was
associated with decreased survival at ﬁve years (38% [±5]) vs no MR
(61% [±6]) (p b 0.001) [12]. Increased ERO was associated with poorer
ﬁve-year survival rates (0 mm2, 61% [±6]; 1–19 mm2, 47% [±8];
≥20 mm2, 29% [±9], p b 0.0001), as was increased RVol (0 mL, 61%
[±6]; 1–29 mL, 44% [±9]; ≥30 mL, 35% [±7], p b 0.0001) [12]. It can
be inferred from the seven identiﬁed publications that severe MR is as-
sociated with a lower survival rate than MR of lesser severity.
3.2.2. Mortality/survival associated with organic MR
Mortality/survival outcomes in patients with OMR were reported in
eleven publications [18,20–26,30,31,35]. No publications clearly report-
ed mortality rates for MR versus no MR.
Two publications reported a relationship between increasing sever-
ity of MR and greater mortality [18,26]. In patients with asymptomatic
OMR of at least a mild degree of severity (mean age 63 years [±14]),
each 10 mm2 increment in the ERO, was associated with a risk ratio
for all-cause mortality of 1.20 (95% CI 1.07–1.34, p b 0.01 [adjusted for
confounders such as age, presence of diabetes, atrial ﬁbrillation [AF]
at baseline, and EF]) [18]. An increase in ERO was an indicator of MR
progression [19]. Theﬁve-yearmortality ratewas 14% (±3) in the over-
all study population and increased from 3% (±2) in patients with an
ERO b20 mm2 to 36% (±9) among those with an ERO of ≥40 mm2
(p b 0.01). The risk of all-cause mortality (adjusted RR 2.90 [95% CI
1.33–6.32], p b 0.01) and death from cardiac causes (adjusted RR 5.21
[95% CI 1.98–14.40], p b 0.01) was greater with an ERO ≥40 mm2 vs
ERO b20 mm2 (adjusted RR 2.90 [95% CI 1.33–6.32], p b 0.01) [18]. In
the second publication, Rusinaru et al. suggested that left atrial (LA)
enlargement size was indicative of more advanced MR and determined
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tality vs LA b55 mm (adjusted HR per 1 mm diameter increment 1.08
[95% CI 1.04–1.12], p b 0.001) [26]. Hence, it can be assumed from
data provided in both publications that severe OMR is associated with
a greater mortality risk than lower grades of severity.
Two publications described linearised annual rates for mortality
[21,23]. The ﬁve-year incidence of total mortality in non-surgically
managed patients with OMR due to ﬂail leaﬂet was estimated at
14% (±4) by Grigioni et al., 2008, with a linearised annual rate of 2.6%
[21]. The majority of patients (97%) were classiﬁed as having Grade III
to IV MR by Doppler echocardiography [21]. Linearised annual rates in
patients with OMR due to ﬂail leaﬂet were also reported by Ling et al.;
6.3% for all-cause mortality (ﬁve-year rate: 28 [±4]; 10-year rate: 43
[±7]) and 4.3% for cardiac death (ﬁve-year rate: 21 [±4]; 10-year
rate: 33 [±7]) [23]. The majority of patients (87%) were classiﬁed as
having Grade III+ or IV+ MR by Doppler echocardiography [23]. The
all-causemortality rate was signiﬁcantly higher than that of the general
US population (p = 0.016) [23].
In addition to Grigioni et al., 2008, and Ling et al., overall mortality
and/or cardiac mortality were described in ﬁve further publications
[22,24,26,30,35]. Kang et al. reported a seven-year cardiac mortality
rate of 5% (±2) in non-surgicallymanaged patients with asymptomatic
severe OMR (mean age 49 years [±14]) [22]. In later abstracts related to
the same study, 10-year cardiacmortalitywas reported at 7% (±2) [35].
Five-year cardiac mortality (14% [±2.6]) was reported by Le Tourneau
et al.; however, the included patients had mild to severe OMR and the
study is not reﬂective of a truly severe population [30]. Cardiacmortality
was also considered by Montant et al. [24]; a non-surgical approach
to managing asymptomatic severe OMR in patients aged b80 years
(mean age 64 years [±15])was associatedwith an increased risk of car-
diac mortality based on 10-year propensity matched, score-adjusted
HRs (HR 4.83 [95% CI 1.84–12.6]). Montant et al. also noted an increased
risk of overall mortality at 10 years (HR 5.21 [95% CI 2.56–10.60]) [24].
Finally, Rusinaru et al. used a multivariable analysis to demonstrate
that LA diameter ≥55 mm was independently associated with overall
mortality (HR 3.67 [95% CI 1.95–6.88], p b 0.001) and cardiac death
(HR 3.74 [95% CI 1.72–8.13], p b 0.001) [26]. All ﬁve publications suggest
an association between severe OMR and increased mortality.
One further study assessed mortality in patients with OMR [20];
however, the risk of death associated with MR vs no MR was not cap-
tured. Rather, Grigioni et al. reported on the risk of death related to
the presence/absence of AF [20]. In multivariate analysis, onset of AF
in patients with MR due to ﬂail leaﬂets was independently associated
with a greater mortality risk in comparison with persistent sinus
rhythm (adjusted RR 2.02, p = 0.056) [20].
Survival rates in patients with OMR were lower than the general
population in two publications [20,24]. Firstly, the 10-year survival
rate of patients with OMR due to ﬂail leaﬂets was lower than that of
an age- and gender-matched US population (53% vs 64%, respectively,
p = 0.051) [20]. Secondly, long-term overall survival (10-year) was
lower inmedically/conservativelymanaged patients with asymptomat-
ic severe OMR vs an age- and gender-matched Belgian population
(demonstrated via Kaplan–Meir curves) [24].
The Austrian general population was considered by Rosenhek et al.,
however the severe OMR population was a combined surgical/watchful
waiting group [25] and no comparison was made between watchful
waiting and the surgical groupor the general population.Overall surviv-
al did not differ between the general population and the surgical/
watchful waiting group [25]. Survival free of any indication for surgery
was 92% (±2) at two years and gradually decreased to 55% (±6) at
eight years [25]. No signiﬁcant difference in event-free survival was
noted for patients with MR due to ﬂail leaﬂet or valve prolapse [25].
In two publications survival rates in patients with severe OMR were
lower than milder MR using proxy measures [18,26]. Rusinaru et al.
determined that eight-year survival was lower in patients with OMR
due to ﬂail leaﬂets with LA ≥55 mm vs LA b55 mm (40% [±9] vs 77%[±4]) [26]. As increased LA diameter appears to be indicative of more
advanced MR [26], it seems reasonable to infer that severe OMR is
associated with a lower survival rate than milder MR. A relationship
between increasing severity ofMR (according to ERO) and lower surviv-
al was noted by Enriquez-Sarano et al. [18,26]. In patients with asymp-
tomatic OMR the survival rate was 96% (±1) at one year and 78% (±3)
at ﬁve years [18,26]. A higher 5-year survival rate was noted with an
ERO b20 mm2 (91% [±3]) versus ERO of 20–39 mm2 (66% [±6]) and
ERO≥40mm2 (58% [±9], p b 0.01) in patientswithmedicallymanaged
MR. In the overall population or in the groupwith an ERO b20mm2 the
observed 5-year survival rates did not differ from the expected ones, but
were signiﬁcantly lower with ERO 20 to 39mm2 (66% vs 84%, p= 0.04)
and ≥40 mm2 (58% vs 78%, p = 0.03) [18]. Both publications demon-
strate a poorer prognosis with severe MR in comparison with MR of
lesser severity.
Survival rates in medically/conservatively managed patients
with OMR appeared to be lower in comparison with surgery in four
publications [21–24]. Long-term survival (10-year) in patients with
asymptomatic severe OMR was lower with medical/conservative man-
agement as opposed to early surgery (overall survival: 50% [±7] vs 86%
[±4], respectively, p b 0.0001; cardiovascular survival: 69% [±7] vs 93%
[±3], respectively, p b 0.0001; event-free survival: 21% [±7] vs 80%
[±4], respectively, p b 0.0001) [24]. A higher rate of survival was also
observed in surgically managed patients with asymptomatic severe
OMR; however, the comparator group received no intervention [22].
The estimated actuarial seven-year event-free survival rate was 99%
[±1] in the surgical group vs 85% [±3] in the no intervention arm
(p b 0.001) [22].
Grigioni et al. estimated the overall ﬁve-year survival rate of non-
surgically managed patients with asymptomatic/minimally symptom-
atic severe MR at 86% [±4%] [21]. Overall ﬁve-year survival after mitral
valve surgery was estimated at 89% [±2], rising to 92% [±2] in patients
who underwent mitral valve repair (rather than replacement) [21].
The fourth publication included survival inmedically managed and sur-
gically treated patients with OMR due to ﬂail leaﬂets and demonstrated
that long-term (10-year) survival was nearly 60% with medical man-
agement and 66% [±4] after surgery. It should be noted that a direct
comparison between the modalities was not explicitly performed [23].
Although surgery appears to be of beneﬁt in patients with severe MR,
a comparison between surgical and medical management strategies
was not the focus of this review and therefore these results should be
viewed with caution.
One additional publication reported ﬁve-year survival free of symp-
toms warranting referral for operation in asymptomatic/minimally
symptomatic severe OMR at 72% and the annual rate of progression to
surgery was expected to be 10.3%; however, no comparison was made
regarding survival rates associated with surgery [28].
3.2.3. Mortality/survival associated with mixed population
(functional/organic MR)
Mortality outcomes in MPMR were reported in three publications
[36–38]. No publications clearly reported mortality rates for MR vs
non-MR. Survival outcomes inMPMRwere reported in two publications
[38,39].
Mirabel et al. reported that in patients with symptomatic severe MR
(mean age 66 years [±13]), therapeutic decision was not a signiﬁcant
predictor of one-year mortality (HR no intervention vs operate 1.08
[95% CI 0.50–2.33], p = 0.85) [38]. However, age (per 10 year increase;
HR 1.73 [95% CI 1.18–2.53], p= 0.005) and Charlson comorbidity index
(per one point increase; HR 1.48 [95% CI 1.27–1.73], p b 0.0001) were
predictive factors of mortality at one year [38].
The remaining two studies demonstrated a greater mortality risk
associated with increasing MR severity [36,37]. Baskett et al. reported
that, after adjusting for confounders, the presence of MR of any grade
(in patients aged between 21 and 80 years) was associated with a
49% increase in all-cause mortality/hospitalisation for HF vs no MR
Table 4
Linearised annual morbidity rates in patients with MR due to ﬂail leaﬂets.
Linearised annual morbidity rates
Ling et al. [23] Grigioni et al. [20] Grigioni et al. [21]a
• CHF: 8.2%
• Chronic AF: 2.2%
• Thromboembolism: 1.9%
• Haemorrhage: 0.4%
• Endocarditis: 1.5%
• MV surgery: 20.0%
• MV surgery or death: 26.3%
• New-onset AF: 5.4%;
• HF: 8.0%
• HF/CVD: 9.3%
AF/HF/CVD: 12.4%
• AF: 5.0%a
Abbreviations: AF, atrial ﬁbrillation; CVD, cardiovascular disease; HF, heart failure; MR,
mitral regurgitation; MV mitral valve.
a Incidence rate of AF was similar in patients with MR due to MVP.
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composite endpoint was noted for Grade II or III MR than Grade I vs no
MR (after adjusting for confounders: Grade I RR 1.55 [95% CI 0.76–3.14];
Grade II or III RR 2.20 [95%CI 1.01–4.80], p=0.05) [36]. The incidence of
all-causemortality was 10 per 100 person-years for MR and six per 100
person-years without MR (p = 0.17) [36]. Finally, the retrospective
analysis by Conti and Mills suggested that in patients awaiting heart
transplantation, Grade III or IV MR was a predictor of early mortality
[37]. Both publications indicate that severe or moderate/severe MR is
associated with a greater risk of mortality than MR of lesser severity.
According toMirabel et al., in patientswith severe, symptomaticMR,
one-year survival was lower in thosewhowere ineligible for surgery vs
surgical management (89.5% [±2.3] vs 96.0% [±1.4], p = 0.02) [38].
The further publication also described patients with severe MR and re-
ported an actuarial survival rate of 51.5% (±7.4) at ﬁve years in those
who did not undergo surgery vs 76.2% (±3.8) in surgically-treated pa-
tients [39]. Both studies indicate that the survival rate is lower in pa-
tients with severe MR who do not receive surgery.
One further publication considered patients with MPMR, but only
described survival (as freedom fromcardiac death) in anOMR subgroup
(Kaplan–Meier six months: 86%; 12 months: 79%) [40].
3.2.4. Morbidity
Morbidity associated with FMR was reported in three publications
[9,10,14], OMR in 12 publications [18–25,27,28,30,31], and a mixed
population (functional/OMR) in one publication [38].
Captured morbidity outcomes included cardiac events such as HF or
AF [9,18,20–25,30], heart transplant [9], hospitalisation due to worsen-
ing HF [10,14], MR progression [19], surgical intervention [18,22–25,
28], Charlson comorbidity index [38], development of symptoms and/
or LV dysfunction [31] and reduced social functioning and vitality [27].
Linearised annual morbidity rates were reported in three studies
which included a population with OMR due to ﬂail leaﬂets [20,21,23]
and one publication that considered MR due to mitral valve prolapse
(MVP) [20] (Table 4).
A known morbidity associated with MR is AF. It has been suggested
that the incidence of AF onset in conservatively managed patients is
high and similar regardless of whether MR is due to MVP or ﬂail leaﬂets
[20]. The following baseline predictors of time to AFwere identiﬁed: ad-
vancing age (MR due to ﬂail leaﬂets: RR per year 1.05 [95% CI 1.02–
1.07], p = 0.0001; MR due to MVP: RR per year 1.05 [95% CI 1.03–
1.07], p b 0.0001), comorbidity (MR due to ﬂail leaﬂets: RR 0.52 [95%
CI 0.30–0.94], p = 0.045) and LA dimension (MR due to ﬂail leaﬂets:
RR per mm 1.06 [95% CI 1.03–1.10], p = 0.0006; MR due to MVP: RR
per mm 1.07 [95% CI 1.04–1.10], p b 0.0001) [20]. Only age and LA
dimensionwere shown to be independent predictors of AF in multivar-
iate analysis [20]. Multivariate analysis also demonstrated that onset of
AF in patients with OMR was independently associated with a greater
risk of CHF in comparison with persistent sinus rhythm (adjusted RR
2.02, p = 0.056) [20].
Atrial ﬁbrillation was considered as one of a series of complications
(including CHF and chordal rupture, mitral valve replacement, infective
endocarditis, cerebral embolism, and cardiac death) associated with
OMR in patients withMVP in the publication fromKim et al. who deter-
mined that severity ofMRwas an independent predictor of the develop-
ment of complications (p = 0.001) [32]. Severe OMR was associated
with a poorer prognosis in terms of cardiac event-free survival com-
pared with no MR/MR of lesser severity (p b 0.01 vs moderate MR)
[32].
Morbidities such as AF and pulmonary hypertension lead to a poorer
prognosis for patients with MR; Montant et al. demonstrated that over-
all survival in conservatively managed patients with severe OMR was
only 8% (±8) at 10 years with these complications at baseline [24].
Two publications considered morbidity in MPMR [36,38]. Baskett
et al. observed that patients with MR were more likely to die or be
hospitalised for HF versus those without MR (log-rank test p = 0.0006for composite endpoint) [36]. Mirabel et al. reported that a higher
Charlson comorbidity index was linked with a decision not to operate
in patients with severe, symptomatic MR (OR per point increase 1.38
[95% CI 1.12–1.72], p = 0.004) [38].
Functional MR was shown to be a key predictor for outcomes with
HF [14]. An increased risk of hospitalisation due to worsening HF with
increasing MR severity was observed by Rossi et al. (severe HR 2.7
[95% CI 2.1–3.5], p = 0.0001; mild/moderate HR 1.3 [95% CI 1.04–1.7],
p = 0.02; versus no MR) [14]. In contrast, Ciofﬁ et al. found that there
was no association between MR and hospitalisation due to worsening
HF (p= 0.41) and that there was no signiﬁcant difference in worsening
CHF-free survival betweenMRof varying severity (absent/mildMR65%,
moderate/severe MR 45%; log rank 0.48) [10].3.2.5. Risk factors associated with OMR
A number of risk factors, for example age, AF, LV and LA dimensions,
and pre-hospital thrombolysis are associated with the presence of MR
and are important predictors of survival, mortality, morbidity, and car-
diac events.
Increasing ERO was identiﬁed as a key factor in the progression of
OMR [19,22]. Enriquez-Sarano et al. [19] identiﬁed mechanisms associ-
ated with increased ERO (and therefore key determinants of MR
progression), such as valvular lesions at baseline, development of a
new ﬂail leaﬂet, and reduced leaﬂet coaptation due to mitral annular
enlargement. In a later publication, Enriquez-Sarano et al. [18] reported
that in severe OMR (i.e. ERO ≥40 mm2) there was an increased risk of
cardiac events (death from cardiac causes, HF or new AF; RR 5.66
[95% CI 3.07–10.56], p b 0.01) versus ERO b20 mm2. Baseline ERO has
also been described as signiﬁcantly greater (p = 0.013) in patients
with asymptomatic severe MR who develop surgical indications vs
thosewho do not [22]. Furthermore, EROwas an independent predictor
of late development of surgical indications or CHF (HR 2.06 [95% CI
1.11–3.82], p = 0.02) [22].
Ejection fraction (EF) was identiﬁed as a key risk factor associated
with MR in three publications [21,23,28]. Baseline LVEF was indepen-
dently predictive of survival in patients with MR due to ﬂail leaﬂet
(adjusted HR per EF% 0.96 [95% CI 0.93–0.98], p = 0.001) [23]. In a sim-
ilar patient population, Grigioni et al. observed that LVEF was an inde-
pendent predictor of cardiac events (AF, HF, or CVD; adjusted HR for
EF% 0.96 [95% CI 0.93–0.98], p= 0.001) [21]. Change in right ventricular
EF from exercise to rest was identiﬁed as an independent predictor of
progression (p = 0.027) in patients with asymptomatic/minimally
symptomatic severe MR [28].
The association of LVESD (left ventricle end systolic diameter) with
MR was reported in one publication [21]. Grigioni et al. demonstrated
that LVESD was a predictor of cardiac events in univariate analysis
(p = 0.016) but independent signiﬁcance was not retained in Cox pro-
portional hazards analysis (p = 0.73) [21].
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(LAVI) as risk factor in OMR [30,31]. In the ﬁrst publication which de-
scribed patients with moderate/severe OMR, LAVI ≥55 mL/m2 was as-
sociated with signiﬁcantly lower event-free survival (development of
symptoms and/or LVdysfunction) at 1, 2 and 3 years comparedwith pa-
tients with LAVI b55 mL/m2 (p = 0.0001) [31]. In the second publica-
tion, Le Tourneau et al. found that the incidence of cardiac events was
signiﬁcantly higher in patients with LAVI ≥60 mL/m2 vs b60 mL/m2
(p = 0.0014) in moderate and severe OMR subgroups [30]. However,
LAVI ≥60 mL/m2 (vs b60 mL/m2) was associated with a signiﬁcantly
higher mortality risk at 5 years in the severe OMR subgroup only
(p = 0.0009) [30].
A further risk factor associated with MR was NYHA class [23]. Base-
line NYHA class was an independent predictor of survival (adjusted
HR per class 1.93 [95% CI 1.45–2.59], p= 0.001) [23] and cardiac events
(AF, HF, or CVD; adjusted HR for Classes III to IV 2.93 [95% CI 1.62–5.32],
p b 0.001).
Agewas identiﬁed as a risk factor for severalmorbidity andmortality
outcomes related toMR. For example, age was identiﬁed as an indepen-
dent predictor of the risk of cardiac events (p b 0.01) in asymptomatic
OMR [18]. An association between baseline age and survival was also
identiﬁed in patients with MR due to ﬂail leaﬂet (adjusted HR per year
of age: 1.08 [95% CI 1.05–1.12], p=0.001) [23]. In patients with asymp-
tomatic severe MR who went on to develop surgical indications, base-
line age was signiﬁcantly higher in comparison with those who did
not reach surgical criteria (p = 0.019) and was an independent
predictor of late development of surgical indications or CHF (HR 1.02
[95% CI 1.01–1.04], p = 0.005) [22]. Singh et al. also found that age
(≥45 years vs b45 years) was a risk factor for surgical indications
after 11 year follow-up in patients with severe MR due to MVP [29].
The presence of AF as a key risk factor associated with MR was
described in one publication and was considered an independent pre-
dictor of the risk of cardiac events (p = 0.05) in patients with asymp-
tomatic OMR [18].
Diabetes was identiﬁed as a key risk factor associated with MR
in two publications [18,22]. Diabetes was determined to be an indepen-
dent predictor of the risk of cardiac events (p b 0.01) in patients with
asymptomatic OMR [18]. Baseline incidence of diabetes was also
shown to be signiﬁcantly higher in patients with asymptomatic severe
MR who went on to develop surgical indications in comparison with
those who did not reach surgical criteria (p = 0.009) [22].
Two publications were identiﬁed which considered the association
of brain natriuretic peptide (BNP) with outcomes in OMR [33,34].
In the ﬁrst publication, BNP level was found to be an independent pre-
dictor of survival in patients with mild to severe MR (adjusted HR per
10 pg/mL 1.23 [95% CI 1.07–1.48]; p = 0.004) [33]. Secondly, Pizarro
et al. found that BNP ≥105 pg/mL was an independent predictor of LV
dysfunction or death (OR 4.6 [95% CI 2.7–11.6]; p b 0.0001) [34].
Finally, a signiﬁcantly higher baseline end-diastolic dimension
(p = 0.007), pulmonary hypertension grade (p = 0.045), and inci-
dence of ﬂail leaﬂets (p = 0.015) was noted in patients with asymp-
tomatic severe MR who went on to develop surgical indications
versus those who did not [22]. Pulmonary hypertension grade was
also an independent predictor of late development of surgical indica-
tions or CHF (HR 1.87 [95% CI 1.22–2.87], p = 0.003) [22].3.2.6. Additional risk factors associatedmixed population (functional/OMR)
Only one publication was identiﬁed which considered risk factors in
MPMR [38]. Mirabel et al. reported that a lower LVEF (OR per 10% 1.39
[95% CI 1.17–1.66], p = 0.0002), non-ischaemic aetiology (OR vs non-
ischaemic 4.44 [95% CI 1.96–10.76], p = 0.001), advancing age (OR
per 10 year increase 1.40 [95% CI 1.15–1.72], p = 0.001) and Grade III
MR (OR vs Grade IV 2.23 [95% CI 1.28–3.29], p = 0.001) were all linked
with a decision not to operate in patients with severe, symptomatic MR
[38].3.2.7. Quality of life associated with MR
Only one publication reported quality of life outcomes [27]. Moder-
ate/severe OMR was associated with poorer social functioning and
lower vitality (both measured using the SF-36) versus no/mild MR
[27].
4. Discussion
The current review supports the published literature with regard to
the excessmortality andmorbidity associatedwithMR and is one of the
most comprehensive reviews conducted in this area.
The identiﬁed studies were extremely heterogeneous in nature, par-
ticularly with regard to the criteria used to assess MR severity. The use
of a recognisedmethod for gradingMR severity is important as previous
authors have determined that quantitative grading of MR is a predictor
of the clinical outcome of medical management [18]. The ability to dis-
tinguish mild from severe MR is vitally important as asymptomatic
patients with severe MR may be indicated for surgery [41]. Both the
ESC/EACTS and the ACC/AHA have described criteria for determining
MR severity, however, only 20 of the 30 identiﬁed publications used
methods which could be correlated to ESC/EACTS and/or ACC/AHA
guidelines [9,10,12,16,18–22,24–26]. Typically, older studies published
prior to recommendations by Zoghbi et al. [42] did not appear to follow
standard criteria. However, even when techniques used to deﬁne MR
severity were in accordance with current guidelines, the cut-off values
for each category (from mild to severe) were frequently not clear. Pop-
ulations described as moderate in one publication could potentially be
classiﬁed as a different grade according to another author. Therefore,
only naïve comparisons between studies were appropriate.
Irrespective of criteria for MR grading, study characteristics, and
patient population, MR was consistently associated with a greater risk
of mortality/poorer survival rates which appeared to rise with increas-
ing severity. Although the association between increasing MR severity
and a greater mortality risk was clear, there was a paucity of data com-
paring all-causemortality inMR vs noMR. Data were only identiﬁed for
FMR and, where reported, all-cause mortality rates ranged from 50% to
71% for FMR and 0% to 39% for no MR [10–12]. However, each of the
studies considered different follow-up times and patient groups; com-
parisons should therefore be viewed with caution. It can be inferred
from the overall data set that severe MR is associated with a greater
risk of mortality in comparison with MR of lower severity.
Even in patients with favourable clinical parameters at baseline [21],
MR was associated with considerable cardiac mortality and morbidity,
suggesting the need for improvedmanagement strategies. Themajority
of identiﬁed publications suggested that early surgerymay be of beneﬁt
in suitable candidates [18,21–24]. Only one publication suggested that a
watchful waiting strategywas acceptable in patients with asymptomat-
ic severe OMR [25]. The management of asymptomatic MR is a conten-
tious issue and there is a paucity of data regarding surgery [5].
Despite the possibility of surgery in patients with symptomatic MR
who are not contraindicated for this approach, a study in 2007 demon-
strated that 49% of patients with symptomatic severe MR were denied
surgery [38]. This is corroborated in a 2009 publication which reported
that although the majority of patients with severe MR presented with
surgical indications according to accepted guidelines, only approxi-
mately 50% received surgery [40]. The current review found that pa-
tients who did not undergo surgery for MR tended to have a poorer
long-term prognosis than those who received surgery, although the lit-
erature searches were not designed to explore the evidence relating to
surgical treatment for MR. A recent study by Suri et al. has indicated
that early surgery among registry patients with MR due to ﬂail leaﬂets
is associated with greater long-term survival compared with medical
management even in those without traditional indicators for surgery
[43]. Medical management is a common treatment approach in MR,
however, its role may also be limited. For example, in acute severe
MR, the role of medical therapy is primarily for stabilising
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Patients are left with even fewer treatment options should medical
and cardiac resynchronization therapy not reduce/resolve MR [44].
The current ESC/EACTS guidelines indicate that in patients with symp-
tomatic severe FMRwho fulﬁl eligibility criteria and have a high surgical
risk, the percutaneous mitral clip procedure may be considered [5]. Re-
search is currently ongoing into percutaneous interventions to assess
their validity in the treatment of functional and organic MR, especially
for patients with severe MR and a high surgical risk.
The presence ofmoderate/severeMR appeared to be associatedwith
quality of life decrements (particularly in social functioning and vitality)
[27]. However, limited data were available from the identiﬁed publica-
tions and although the negative impact ofMRon quality of life seems in-
tuitive, it is not yet substantiated, indicating an area for further research.
Prognosis and preoperative risk evaluation remain difﬁcult and have
to take into account a comprehensive approach. In severe MR the
presence of risk factors can increase morbidity and mortality and lead
to a poorer long-term prognosis [2]. Several risk factors were identiﬁed
as predictors of mortality, such as age, increasing NYHA class, presence
of AF, and diabetes. Michelena et al. have suggested that each patient
with severe OMR should be evaluated individually and their manage-
ment should take into account the presence of risk factors [2]. It is
clear that management is challenging in patients with MR and that
the prognosis is poor in inappropriately managed patients [2]. This re-
view underscores the burden ofMR in terms of morbidity andmortality
and the need to raise awareness for earlier and dedicated management
of functional and organic MR.
The current literature review demonstrates that there is a lack of
published clinical trial data, particularly assessing outcomes in patients
with severe MR who are contraindicated for surgery. A recent publica-
tion by Bonow also suggested that the management of patients with
valvular disease has been hindered by the lack of prospective clinical
trials [6]. It is apparent, however, thatMR is associatedwith excessmor-
tality and morbidity and that there is an unmet need in the manage-
ment of the condition, particularly for those patients who have who
have FMR, are not indicated for surgery, or have unresolved MR after
surgery. As mortality and morbidity increase with MR severity, patients
with severe MR represent the greatest need for alternative therapy
when surgery has failed or is contraindicated.
4.1. Study limitations
Due to the heterogeneity of the included studies and variations in
the criteria used to deﬁne MR severity, the ﬁndings of this research
need to be viewed with caution, as does the applicability of data to the
wider population of patients with MR. Differences in health care sys-
tems may also inﬂuence the validity of results. Finally, publication
bias, leading to a tendency to publish paperswhereMRwas a signiﬁcant
predictor of outcome cannot be ruled out.
5. Conclusion
The current review is one of the most comprehensive literature
searches conducted in the medical/conservative management of mitral
regurgitation. Key ﬁndings from the review illustrate that, irrespective
of study characteristics and patient population, the presence of MR
(functional or organic) is associated with an increased risk of mortality
andmorbidity comparedwith noMR— a riskwhich appears to progres-
sively increasewith greater severity ofMR. Therefore, effectivemanage-
ment is particularly needed in patients with severe MR at high risk for
surgery. Earlier referral expertise centres as well as further research
into alternativemanagement strategies, such as percutaneous interven-
tion, are needed particularly to improve the prognosis of patients who
are contraindicated to surgery and at a high risk of mortality and
morbidity.Conﬂicts of interest
FG: Participation in Abbott advisory board and serving as an investi-
gator on a clinical trial.
JNT: Participation in Abbott advisory board and Abbott symposium.References
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